A new partnership has been set up between the Ella Dawson Foundation, a UK-based charity for young people with cancer, and ...

Welcome to the second edition of the new Changing Faces Board round-up. The pharmaceutical sector saw a wave of significant ...

In the ad for oral CGRP inhibitor Ubrelvy (ubrogepant), Williams is depicted as suffering from a migraine while in a talk ...

Zynyz (retifanlimab) is a late entrant to the PD-1/PD-L1 category but picked up its first approval in the rare tumour Merkel ...

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD ...

The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona this weekend – ...

In the study, MILTON was used to analyse 3,200 diseases and achieved a high prediction score for 1,091 of them. It can be ...

Olorofim is licensed in Europe and Asia to Japanese pharma Shionogi, which paid $100 million upfront for rights to the drug ...

Indeed, the global oncology community trusts ESMO to disseminate the latest results of cancer research. Why? Because it is ...

It's known that excessive use of earbuds at high volumes can cause hearing loss, so somewhat ironic that the FDA has just ...

The $25 million award from the Advanced Research Projects Agency for Health (ARPA-H) will be used to develop Cellino's NEBULA ...

There are no FDA-approved therapies for this age group, although, Wegovy has been cleared since 2022 for use in children and ...